» Articles » PMID: 39617892

Peripheral Artery Disease, Antithrombotic Treatment and Outcomes in European and Asian Patients with Atrial Fibrillation: Analysis from Two Prospective Observational Registries

Abstract

Background: In patients with atrial fibrillation (AF), the impact of peripheral artery disease (PAD) on oral anticoagulant (OAC) therapy use and the risk of outcomes remains unclear.

Objective: To analyse the epidemiology of PAD in a large cohort of European and Asian AF patients, and the impact on treatment patterns and risks of adverse outcomes.

Methods: We analysed AF patients from two large prospective observational registries. OAC prescription and risk of outcomes were analysed according to the presence of PAD, using adjusted Logistic and Cox regression analyses. The primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). Interaction analyses were also performed.

Results: Fifteen-thousand-four-hundred-ninety-seven patients with AF (mean age 68.9, SD 11.6 years; 38.6% female, 30% from Asia) were included in the analysis. PAD was found in 941 patients (6.1%), with a higher prevalence among European individuals compared to Asian (8.1% vs 1.2%, p < 0.001). On logistic regression analysis, European patients had sixfold higher odds of presenting with PAD compared with Asians (OR 6.23, 95% CI 4.75-8.35). After adjustments, PAD was associated with lower use of OAC (OR: 0.59, 95% CI: 0.50-0.69). On Cox regression analysis, PAD was associated with a higher risk of the primary composite outcome (HR 1.28, 95% CI: 1.08-1.52) and all-cause death (HR 1.40, 95% CI: 1.16-1.69). A significant interaction was observed between PAD and age, with higher effects of PAD found in younger patients (< 65 years) for the risk of the primary outcome (p = 0.014).

Conclusions: In patients with AF, PAD is associated with lower use of OAC and a higher risk of adverse outcomes, with a greater risk seen in younger patients.

Citing Articles

Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential.

Thakkar B, Dadhaniya H, Dudhat K Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39888363 DOI: 10.1007/s00210-025-03819-3.


Association of elevated albumin-corrected anion gap with all-cause mortality risk in atrial fibrillation: a retrospective study.

Xu J, Wang Z, Wang Y, Chen X, Ma L, Wang X BMC Cardiovasc Disord. 2025; 25(1):55.

PMID: 39871159 PMC: 11771038. DOI: 10.1186/s12872-025-04518-w.

References
1.
Shakir A, Khan A, Agarwal S, Clifton S, Reese J, Munir M . Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2022; 66(2):493-506. DOI: 10.1007/s10840-022-01347-1. View

2.
Bucci T, Proietti M, Shantsila A, Romiti G, Teo W, Park H . Integrated Care for Atrial Fibrillation Using the ABC Pathway in the Prospective APHRS-AF Registry. JACC Asia. 2023; 3(4):580-591. PMC: 10442886. DOI: 10.1016/j.jacasi.2023.04.008. View

3.
Proietti M, Farcomeni A . Association Between Peripheral Artery Disease and Incident Risk of Atrial Fibrillation: Strong Evidence Coming From Population-Based Cohort Studies. J Am Heart Assoc. 2018; 7(8). PMC: 6015415. DOI: 10.1161/JAHA.118.009126. View

4.
Levy P . Premature lower extremity atherosclerosis: clinical aspects. Am J Med Sci. 2002; 323(1):11-6. DOI: 10.1097/00000441-200201000-00003. View

5.
Tse H, Teo W, Siu C, Chao T, Park H, Shimizu W . Prognosis and treatment of atrial fibrillation in Asian cities: 1-year review of the Asia-Pacific Heart Rhythm Society Atrial Fibrillation Registry. Europace. 2022; 24(12):1889-1898. DOI: 10.1093/europace/euab327. View